SNSE

Significant stock events in the past six months include the announcement of a strategic review and discontinuation of solnerstotug development on October 30, 2025, and the report of third-quarter 2025 financial results on November 14, 2025. On February 18, 2026, the company announced the acquisition of Faeth Therapeutics and a $200 million private placement, leading to a significant stock price increase. Inducement grants of stock options to new employees were announced on February 19, 2026, and March 17, 2026. The company reported full-year 2025 financial results and provided a corporate update on March 30, 2026. Sensei Biotherapeutics presented at the 25th Annual Needham Virtual Healthcare Conference on April 9, 2026, and dosed the first patient in its Phase 1b/2 trial of PIKTOR on May 5, 2026.